Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

@article{Levine2007RoleOJ,
  title={Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders},
  author={Ross L. Levine and Animesh Pardanani and Ayalew Tefferi and Dwight Gary Gilliland},
  journal={Nature Reviews Cancer},
  year={2007},
  volume={7},
  pages={673-683}
}
The myeloproliferative disorders polycythaemia vera (PV), essential thombocythaemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic progenitors. The genetic cause of these diseases was not known until 2005, when several independent groups demonstrated that most patients with PV, ET and PMF acquire a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F). These discoveries have changed the landscape for diagnosis and classification of… CONTINUE READING
Highly Influential
This paper has highly influenced 23 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS